The findings propose that therapeutic strategies targeting these adipokine pathways, particularly modulating leptin and boosting adiponectin, could potentially improve cardiac function and exercise tolerance in individuals suffering from obesity-related cardiovascular dysfunction. Here, ADIPOQ is linked to obesity due to melanocortin 4 receptor deficiency.